Following the latest round of of annual drug reimbursement price cuts announced in March and implemented in April, Japanese regulatory authorities have now announced additional extraordinary price revisions for five products, effective 1 August.
Daiichi Sankyo Co., Ltd.’s Tarlige (mirogabalin) and Viatris Inc.’s Lyrica (pregabalin), both neuropathic pain drugs, along with






